Evidence map›Paper›PMID 24455486›Full record

ReviewFrontiers in oncology2014

Serglycin: at the crossroad of inflammation and malignancy.

Angeliki Korpetinou, Spyros S Skandalis, Vassiliki T Labropoulou, Gianna Smirlaki, Argyrios Noulas, Nikos K Karamanos, Achilleas D Theocharis

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 134 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Angeliki KorpetinouLaboratory of Biochemistry, Department of Chemistry, University of Patras , Patras , Greece.
Spyros S SkandalisLaboratory of Biochemistry, Department of Chemistry, University of Patras , Patras , Greece.
Vassiliki T LabropoulouDivision of Hematology, University Hospital of Patras , Patras , Greece.
Gianna SmirlakiLaboratory of Biochemistry, Department of Chemistry, University of Patras , Patras , Greece.
Argyrios NoulasTechnological Educational Institute , Larissa , Greece.
Nikos K KaramanosLaboratory of Biochemistry, Department of Chemistry, University of Patras , Patras , Greece.
Achilleas D TheocharisLaboratory of Biochemistry, Department of Chemistry, University of Patras , Patras , Greece.
University of Patras · GRGeneral University Hospital of Patras · GRTechnological Educational Institute of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serglycin has been initially characterized as an intracellular proteoglycan expressed by hematopoietic cells. All inflammatory cells highly synthesize serglycin and store it in granules, where it interacts with numerous inflammatory mediators, such as proteases, chemokines, cytokines, and growth factors. Serglycin is implicated in their storage into the granules and their protection since they are secreted as complexes and delivered to their targets after secretion. During the last decade, numerous studies have demonstrated that serglycin is also synthesized by various non-hematopoietic cell types. It has been shown that serglycin is highly expressed by tumor cells and promotes their aggressive phenotype and confers resistance against drugs and complement system attack. Apart from its direct beneficial role to tumor cells, serglycin may promote the inflammatory process in the tumor cell microenvironment thus enhancing tumor development. In the present review, we discuss the role of serglycin in inflammation and tumor progression.

Indexed as

chondroitin sulfateinflammationmalignancyproteoglycansserglycin

Identifiers

PMID24455486
PMCPMC3888995
OpenAlexW2026639823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.